 Interferon-alpha
"Interferon-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
| Descriptor ID |
D016898
|
| MeSH Number(s) |
D12.644.276.374.440.890.250 D12.644.276.718.500.250 D12.776.467.374.440.890.250 D12.776.467.718.500.250 D23.529.374.440.890.250 D23.529.718.500.250
|
| Concept/Terms |
Interferon-alpha- Interferon-alpha
- Interferon alpha
- Interferon Alfa
- Interferon, Lymphoblastoid
- Lymphoblastoid Interferon
- Interferon, Leukocyte
- Leukocyte Interferon
- Interferon, Lymphoblast
- Lymphoblast Interferon
- alpha-Interferon
- alpha Interferon
- Interferon, alpha
Interferon alpha-17- Interferon alpha-17
- Interferon alpha 17
- Interferon alpha-T
- Interferon alpha T
- LeIF I
- Interferon alpha-88
- Interferon alpha 88
Interferon alpha-7- Interferon alpha-7
- Interferon alpha 7
- LeIF J
- Interferon alpha-J
- Interferon alpha J
Interferon alpha-5- Interferon alpha-5
- Interferon alpha 5
- Interferon alpha5
- IFN-alpha5
- IFN alpha5
Interferon alpha-2- Interferon alpha-2
- Interferon alpha 2
- LeIF A
- Interferon alpha-A
- Interferon alpha A
- Interferon-alpha 2
- 2, Interferon-alpha
- IFN-alpha 2
- IFN-alpha-2
|
Below are MeSH descriptors whose meaning is more general than "Interferon-alpha".
Below are MeSH descriptors whose meaning is more specific than "Interferon-alpha".
This graph shows the total number of publications written about "Interferon-alpha" by people in this website by year, and whether "Interferon-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1988 | 2 | 0 | 2 | | 1989 | 2 | 1 | 3 | | 1990 | 3 | 0 | 3 | | 1991 | 1 | 0 | 1 | | 1992 | 5 | 3 | 8 | | 1993 | 5 | 3 | 8 | | 1994 | 3 | 3 | 6 | | 1995 | 2 | 4 | 6 | | 1996 | 3 | 4 | 7 | | 1997 | 4 | 6 | 10 | | 1998 | 2 | 3 | 5 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 4 | 5 | | 2001 | 2 | 3 | 5 | | 2002 | 4 | 6 | 10 | | 2003 | 5 | 5 | 10 | | 2004 | 3 | 4 | 7 | | 2005 | 1 | 1 | 2 | | 2006 | 2 | 5 | 7 | | 2007 | 0 | 1 | 1 | | 2008 | 5 | 2 | 7 | | 2009 | 4 | 6 | 10 | | 2010 | 5 | 7 | 12 | | 2011 | 9 | 4 | 13 | | 2012 | 2 | 3 | 5 | | 2013 | 5 | 0 | 5 | | 2014 | 0 | 1 | 1 | | 2015 | 2 | 4 | 6 | | 2016 | 0 | 1 | 1 | | 2017 | 0 | 2 | 2 | | 2018 | 1 | 1 | 2 | | 2019 | 1 | 0 | 1 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Interferon-alpha" by people in Profiles.
-
Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol. 2020 07; 20(7):397-398.
-
Chen H, Sun J, Zhou B, Xie Q, Liang X, Fan R, Conran C, Xu J, Ji Y, Zhang X, Sun L, Jia J, Wang G, Hou J, Jiang DK. Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha. Clin Gastroenterol Hepatol. 2020 01; 18(1):196-204.e8.
-
Nanayakkara M, Lania G, Maglio M, Auricchio R, De Musis C, Discepolo V, Miele E, Jabri B, Troncone R, Auricchio S, Barone MV. P31-43, an undigested gliadin peptide, mimics and enhances the innate immune response to viruses and interferes with endocytic trafficking: a role in celiac disease. Sci Rep. 2018 Jul 17; 8(1):10821.
-
Coomans de Brachène A, Dos Santos RS, Marroqui L, Colli ML, Marselli L, Mirmira RG, Marchetti P, Eizirik DL. IFN-a induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells. Diabetologia. 2018 03; 61(3):636-640.
-
Tarhini AA, Moschos SJ, Lin Y, Lin HM, Sander C, Yin Y, Venhaus R, Gajewski TF, Kirkwood JM. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-a2b in patients with metastatic melanoma. Melanoma Res. 2017 08; 27(4):342-350.
-
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017 03 09; 376(10):917-927.
-
Slight-Webb S, Lu R, Ritterhouse LL, Munroe ME, Maecker HT, Fathman CG, Utz PJ, Merrill JT, Guthridge JM, James JA. Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity. Arthritis Rheumatol. 2016 10; 68(10):2492-502.
-
Ohguchi A, Yamauchi H, Doi K, Nakayama H. Activation of type I interferon signaling in the parotid and exorbital lachrymal glands during the acute phase of encephalomyocarditis (EMC) virus infection in mice. Exp Mol Pathol. 2016 06; 100(3):434-40.
-
Chiang JJ, Gack MU. Reading the fine print: sequence-specific activation of cGAS. Nat Immunol. 2015 Oct; 16(10):1009-10.
-
Dhanasekaran R, Sanchez W, Mounajjed T, Wiesner RH, Watt KD, Charlton MR. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int. 2015 Nov; 35(11):2433-41.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|